Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer

• Published in: Journal of clinical oncology Vol. 41; no. 6_suppl; p. 524
• Main Authors: Khaki, Ali Raza, Fan, Alice C., Shah, Sumit, Parikh, Divya Ahuja, Chien, Joanne, Moore, Kaidi, Ruiz, Shann Mika, Haas, Denise, Fakhoury, Laith, Del Toro, Noël, Baker, Paige, O'Brien, Aidan, Srinivas, Sandy
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 20.02.2023

524Background: The immune-responsive nature of bladder cancer has made it an active area of interest for novel applications of immune checkpoint inhibitors (ICIs), with multiple ICI agents approved in the metastatic setting and ongoing perioperative trials. Variant histology urothelial carcinoma is...